SOURCE: Elsevier Business Intelligence

December 20, 2010 09:05 ET

Medtech VCs Will Divulge Trends in European Dealmaking and Investing at Elsevier's 'IN3 Europe' Investor Conference in Paris, March 15-16, 2011

42nd IN3 Medical Device Partnering Conference Continues With 'New and Improved' Format

PARIS--(Marketwire - December 20, 2010) - Elsevier Business Intelligence, the medtech industry's leading strategic partnership and investment conference-organizer, announced today that it will host 'IN3 Europe' on March 15-16, 2011, at Le Meridien Montparnasse Hotel, Paris.

Medical device start-ups continue to face intense competition for a finite amount of available funding. IN3 events offer an unparalleled experience for emerging companies to meet and impress potential investors from many of the top-tier device companies and discerning healthcare investment firms from around the world. Leading venture capital firms and corporate acquirers are expected to attend IN3 Europe to hear about the latest innovations and investment opportunities from more than 40 emerging medical technology companies seeking funding and/or strategic partnerships.

Medtech innovator presentations are now mixed within the same time block as VCs, allowing emerging companies to get in front of more potential investment suitors. Plus, IN3 Europe has added more plenary/panel sessions to benefit the needs of all audience members, including special lunch and reception sessions from key sponsors. And, as always, top industry leaders will speak about regulatory issues, hot investment areas, real-life case studies on investing and M&A, philosophy to investments, and more.

IN3 Europe is a must-attend event if you are...

  • An emerging company interested in what investment leaders in the industry are thinking, doing, and planning. Top-tier venture capitalists and corporate acquirers address what interests them most in innovative technologies, therapeutic areas, products, and geographic markets. They will also discuss partnering opportunities, case studies, how to maximize visibility in front of large company investors, and the role of M&A.
  • A business development or financial community leader interested in investment, partnering, or acquisition opportunities with cutting-edge medtech innovators.
  • A service provider or industry affiliate who is seeking to meet and support innovators and market leaders with their business needs.

Upcoming IN3 events: 1) Feb. 22-24, 2011, IN3 West, The Venetian Resort-Hotel-Casino, Las Vegas; 2) June 21-23, 2011, IN3 East, Boston, The Hyatt Regency. For more information about IN3 events, please contact: Kayleen Kell at +1-949-453-0071, or email

About Elsevier Business Intelligence
Elsevier Business Intelligence, an Elsevier company, is a global information supplier providing business intelligence on regulatory, business and reimbursement issues that are vital to the healthcare industry. Through a range of products including publications, conferences, databases and reports, Elsevier Business Intelligence places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge, by providing the perfect combination of news and information together with penetrating insight and analysis. Elsevier Business Intelligence ( has offices in the U.S. in Bridgewater, N.J.; Norwalk, Conn.; Rockville, Md.; and Irvine, Calif.

About Elsevier
Elsevier is a world-leading publisher of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet ( and Cell (, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include Sciverse ScienceDirect (, Sciverse Scopus (, Reaxys (, MD Consult ( and Nursing Consult (, which enhance the productivity of science and health professionals, and the SciVal suite ( and MEDai's Pinpoint Review (, which help research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier ( employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC (, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Contact Information